Brokerages Set Novavax, Inc. (NASDAQ:NVAX) Price Target at $11.25

Shares of Novavax, Inc. (NASDAQ:NVAX) have been assigned a consensus rating of “Hold” from the nine brokerages that are currently covering the stock, MarketBeat.com reports. Four analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $11.8750.

A number of brokerages have commented on NVAX. B. Riley Financial reissued a “buy” rating and set a $16.00 price objective (down from $18.00) on shares of Novavax in a report on Monday, November 10th. Wall Street Zen raised Novavax from a “sell” rating to a “hold” rating in a research report on Saturday. HC Wainwright lifted their price objective on shares of Novavax from $11.00 to $16.00 and gave the stock a “buy” rating in a report on Friday. Weiss Ratings reiterated a “sell (d+)” rating on shares of Novavax in a research note on Monday, December 29th. Finally, TD Cowen dropped their price target on shares of Novavax from $8.00 to $7.00 and set a “hold” rating on the stock in a research report on Tuesday, November 4th.

Institutional Trading of Novavax

A number of institutional investors and hedge funds have recently modified their holdings of NVAX. Flagship Harbor Advisors LLC purchased a new position in Novavax in the fourth quarter worth $33,000. Quarry LP bought a new stake in shares of Novavax during the 3rd quarter worth $33,000. State of Wyoming purchased a new position in shares of Novavax in the 2nd quarter worth about $52,000. Mirae Asset Global Investments Co. Ltd. grew its position in Novavax by 25.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,896 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 1,617 shares during the period. Finally, Danske Bank A S purchased a new stake in Novavax during the third quarter worth about $64,000. 53.04% of the stock is owned by hedge funds and other institutional investors.

Novavax Stock Performance

NVAX opened at $10.14 on Friday. Novavax has a 1-year low of $5.01 and a 1-year high of $11.97. The company has a market cap of $1.65 billion, a price-to-earnings ratio of 4.21 and a beta of 2.58. The company’s fifty day moving average price is $8.34 and its two-hundred day moving average price is $8.03. The company has a current ratio of 2.27, a quick ratio of 2.24 and a debt-to-equity ratio of 5.93.

Novavax (NASDAQ:NVAX) last posted its earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.11 EPS for the quarter, topping the consensus estimate of ($0.66) by $0.77. Novavax had a net margin of 39.19% and a negative return on equity of 836.17%. The company had revenue of $136.40 million during the quarter, compared to the consensus estimate of $90.26 million. During the same period in the previous year, the firm posted ($0.51) earnings per share. The firm’s revenue for the quarter was up 66.6% on a year-over-year basis. On average, analysts expect that Novavax will post -1.46 EPS for the current fiscal year.

Key Stories Impacting Novavax

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Q4 results beat: Novavax reported a surprise GAAP profit (EPS $0.11) and ~67% year‑over‑year revenue growth, driven by licensing/milestone revenues — the core reason the stock jumped on the news. Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates
• Positive Sentiment: Strong operational highlights and balance sheet: Full‑year 2025 revenue of ~$1.1B, $225M Sanofi milestones earned, and year‑end cash of ~$751M reduce short‑term financing risk and support pipeline investments. Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
• Positive Sentiment: Analyst upgrade: HC Wainwright raised its price target to $16 and kept a Buy rating, signaling bullish conviction from at least one sell‑side shop. Benzinga
• Neutral Sentiment: Investor access: Management will present at upcoming investor conferences (TD Cowen fireside chat, others) — useful for transparency but not a near‑term catalyst by itself. Novavax to Participate in Upcoming Investor Conferences
• Neutral Sentiment: Market activity: Unusual options flow showed heavy call buying around the earnings move, indicating elevated short‑term speculative interest. (This reflects trader positioning, not fundamental change.)
• Neutral Sentiment: Earnings call transcript posted for deeper detail on results and guidance assumptions. Novavax, Inc. (NVAX) Q4 2025 Earnings Call Transcript
• Negative Sentiment: 2026 revenue guidance disappointed relative to consensus: Management guided revenue of $230M–$270M for 2026, well below street estimates (~$402M), creating concern about demand trends and prompting profit‑taking. Novavax Q4 Press Release / Guidance
• Negative Sentiment: Analyst caution remains: Some analysts argue the bull case needs more proof despite the beat — concerns on sustainability of licensing revenue, product demand and execution could cap multiple expansion. Novavax: The Bear Case Is Broken, But The Bull Case Needs More Proof

Novavax Company Profile

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.